What's Happening?
Seaport Therapeutics, a clinical-stage therapeutics company, has announced positive results from the multiple-ascending dose (MAD) portion of its Phase 1 proof-of-concept clinical trial for GlyphAgo, a novel oral prodrug of agomelatine. The trial, which
involved healthy volunteers, demonstrated that repeat dosing of GlyphAgo was well tolerated with no serious adverse events, particularly no liver-related issues. The drug showed a consistent safety, tolerability, and pharmacokinetic profile, supporting its further development for treating generalized anxiety disorder (GAD). The company plans to advance GlyphAgo into two Phase 2 trials, with one focusing on its effects on sleep in GAD patients and the other evaluating its efficacy and safety in a broader GAD patient population.
Why It's Important?
The development of GlyphAgo is significant as it addresses the limitations of agomelatine, which include high first-pass metabolism and liver-related side effects. By enhancing bioavailability and reducing liver exposure, GlyphAgo could offer a safer and more effective treatment option for GAD, a condition that has not seen new medication approvals in nearly two decades. This advancement could potentially improve the quality of life for patients suffering from anxiety disorders by providing a novel therapeutic option with fewer side effects, thereby expanding the treatment landscape in neuropsychiatry.
What's Next?
Seaport Therapeutics plans to initiate two Phase 2 trials for GlyphAgo. The first, a Phase 2a trial, will assess the drug's impact on sleep architecture in GAD patients, with results expected in early 2028. The second, a Phase 2b trial, will evaluate the drug's efficacy and safety in a larger GAD patient population, with results anticipated by the end of 2028. These trials will be crucial in determining the drug's potential as a leading treatment for GAD and could pave the way for its eventual approval and commercialization.
